NCT01714739 arm group 6d92f6c0154f3f108b49b425f17c7ed5 [clinicaltrials_resource:NCT01714739/arm-group/6d92f6c0154f3f108b49b425f17c7ed5]
arm group [clinicaltrials_vocabulary:arm-group]
NCT01714739 arm group 6d92f6c0154f3f108b49b425f17c7ed5 [clinicaltrials_resource:NCT01714739/arm-group/6d92f6c0154f3f108b49b425f17c7ed5]
Bio2RDF identifier
NCT01714739/arm-group/6d92f6c0154f3f108b49b425f17c7ed5
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... 92f6c0154f3f108b49b425f17c7ed5
description [clinicaltrials_vocabulary:description]
Lirilumab 0.1 mg/kg solution i ...... 96 weeks depending on response
identifier
clinicaltrials_resource:NCT01714739/arm-group/6d92f6c0154f3f108b49b425f17c7ed5
title
NCT01714739 arm group 6d92f6c0154f3f108b49b425f17c7ed5
@en
type
label
NCT01714739 arm group 6d92f6c0 ...... 2f6c0154f3f108b49b425f17c7ed5]
@en